Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 4, 2017Expert Opinion on Pharmacotherapy

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

View Full Paper
Ask AI
Bookmark
Share

Authors

NUNatalie UyASAbhay SinghSGSteven D. Gore

Discussion

Loading...

Member takes

Overview

Narrative review evaluates treatment strategies for myelodysplastic syndromes, highlighting emerging therapeutic alternatives and investigational approaches following hypomethylating agent failure.

Key Points

  • To evaluate alternative treatment strategies to hypomethylating agents (HMAs) in frontline myelodysplastic syndromes (MDS) and identify viable therapeutic options for patients following HMA failure.
  • Review and synthesis of updated evidence on standard-of-care interventions, including allogeneic stem cell transplantation.
  • Qualitative evaluation of novel molecular biology findings and clinical trial pipelines for frontline and HMA-refractory MDS.
  • Hypomethylating agents remain the standard frontline treatment for MDS, yet the majority of patients experience therapeutic failure within two years.
  • Patients with HMA failure experience poor survival outcomes without an established standard of care.
  • Novel targeted agents and allogeneic transplantation represent critical alternative strategies, with multiple investigational therapies currently advancing in clinical trials.

Cite This Study

Uy et al. (2017) studied this question.

synapsesocial.com/papers/6a1e7dff09554abc3868e11bhttps://doi.org/10.1080/14656566.2017.1349100
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System2008 · 486 citations
  2. 2Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF412016 · 29 citations
  3. 3Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents2016 · 215 citations
  4. 4Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies2016 · 13 citations